Dr. Muhammad Rizwan Sardar, MD

Dr. Sardar practices at Memorial Medical Center in Las Cruces, New Mexico, part of Lifepoint Health.

Dr. Sardar's NPI, 1891029658, was assigned on September 28, 2009. Dr. Sardar holds Ohio license 35.127731.

Dr. Sardar's primary practice is Memorial Medical Center, at 2450 South Telshor Blvd, Las Cruces, NM 88011 in Dona Ana County. The practice phone is (575) 522-8641.

Dr. Sardar's primary practice is Memorial Medical Center in Las Cruces, New Mexico, part of Lifepoint Health. Dr. Sardar is also affiliated with MountainView Regional Medical Center. The medical group on file is New Mexico Cardiovascular Associates. Dmand AI also links Dr. Sardar to 3 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sardar practices, 5 sites in all. Vendor and product names are available with a free account.

Interventional cardiology is Dr. Sardar's primary specialty in the NPI Registry, under taxonomy code 207RI0011X. Dmand AI has Dr. Sardar's licenses on file in 3 states: Ohio, New York and Pennsylvania.

Dmand AI lists angioplasty, cardiac catheterization, circulation problems, leg revascularization and pacemaker or defibrillator implantation among the conditions Dr. Sardar treats.

CMS data shows 4,849 Medicare services from Dr. Sardar across 43 procedure codes in 2024, for 2,067 Medicare patients. Medicare paid $317,198 for them.

CMS counts 2,067 Medicare patients who saw Dr. Sardar in 2024. The largest group is 65 to 74, with 778 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 19% are also on Medicaid. Their average risk score is 1.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sardar's median patient age at 74, with 52% women.

In 2024, Dr. Sardar wrote 3,965 Medicare Part D claims for 625 patients. 84% of them were for generic drugs. CMS names the drug for 3,766 of them, across 38 drugs with 11 or more claims each, at $426,311 in total drug cost. In 2023, CMS named 2,372 claims across 31 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Sardar for performance year 2024, reported as part of a group. Dr. Sardar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sardar as offering telehealth. CMS counts 43 procedures of coronary angioplasty and stenting by Dr. Sardar, more than 79% of the clinicians it reports for that procedure.

Leg revascularization (restoring blood flow): 1 to 10 procedures (CMS shows small counts as a range)

Varicose vein removal: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 21 papers to Dr. Sardar, published from 2012 to 2021. 2014 was the busiest year, with 2. The most frequent topics are Heart Valve Prosthesis, Aortic Valve and Aortic Valve Stenosis. Dr. Sardar has published most often in Cardiovasc Revasc Med. Dr. Sardar's most frequent co-authors are Wajeeha Saeed, MD, Herbert David Aronow, MD and Afshin Ehsan, MD.

CMS Open Payments shows 507 general payments to Dr. Sardar from 54 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 25% of the total. Edwards Lifesciences Corporation paid the most, $23,985.

Dr. Sardar is in network with 22 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 12. Check the plan with the practice before a visit.